Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.44 |
| ▸ | CTSD | P07339 | 2/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892139 | 0.91 | BACE1 (0.39) | BACE1CTSDGRIN2DGRIN3BGRIN1 | |
| SCHEMBL877186 | 0.81 | TNF (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL882561 | 0.75 | BACE1 (0.64) | BACE1CTSD | |
| SCHEMBL891952 | 0.75 | BACE1 (0.64) | BACE1CTSD | |
| SCHEMBL891622 | 0.68 | BACE1 (0.59) | BACE1CTSD | |
| SCHEMBL12827815 | 0.67 | BACE1 (0.49) | BACE1 | |
| SCHEMBL878160 | 0.64 | ACHE (0.55) | SIGMAR1HTR2AHTR2B | |
| SCHEMBL892304 | 0.64 | ACHE (0.55) | SIGMAR1HTR2AHTR2B | |
| SCHEMBL10209459 | 0.64 | BACE1 (0.49) | BACE1CTSD | |
| SCHEMBL892224 | 0.62 | BACE1 (0.48) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
| WO-2012040641-A2 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | BACE1 1/4885CTSD 224/4885GRIN2D 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.